In conclusion, FGF21 analogs must be tested in new clinical trials, as they appear to exhibit great potential for treating signs of Metabolic Syndrome such as high blood insulin, obesity, and especially hypercholesterolemia. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.